The Rutgers Cancer Institute of New Jersey is a cancer treatment and research institution that is a part of Rutgers University and located in New Brunswick, New Jersey.

During the past decade, Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital conducted 63 clinical trials. In the 10-year time frame, 63 clinical trials started and 54 clinical trials were completed, i.e. on average, 85.7% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 34 clinical trials were completed. i.e. 170% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital" #1 sponsor was "Children's Oncology Group" with 60 trials, followed by "National Cancer Institute (NCI)" with 57 trials sponsored, "Alliance for Clinical Trials in Oncology" with 5 trials sponsored, "Eastern Cooperative Oncology Group" with 2 trials sponsored and "NRG Oncology" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 11 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 73 trials as a collaborator, "Radiation Therapy Oncology Group" with 7 trials as a collaborator, "Canadian Cancer Trials Group" with 4 trials as a collaborator, "Children's Oncology Group" with 4 trials as a collaborator and "NRG Oncology" with 3 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 16 trials.

According to Clinical.Site data, the most researched conditions in "Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital" are "Recurrent Neuroblastoma" (9 trials), "Acute Lymphoblastic Leukemia" (8 trials), "Recurrent Osteosarcoma" (8 trials), "Refractory Osteosarcoma" (7 trials) and "Recurrent Hepatoblastoma" (6 trials). Many other conditions were trialed in "Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital" in a lesser frequency.

Most popular intervention types in "Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital" are "Drug" (107 trials), "Other" (77 trials), "Radiation" (50 trials), "Biological" (48 trials) and "Procedure" (43 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (49 trials), "Cyclophosphamide" (36 trials), "Vincristine Sulfate" (31 trials), "Radiation Therapy" (27 trials) and "Etoposide" (26 trials). Other intervention names were less common.

The vast majority of trials in "Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital" are 124 trials for "All" genders and 8 trials for "Female" genders.

Currently, there are NaN active trials in "Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital". undefined are not yet recruiting, 36 are recruiting, 53 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 34 completed trials in Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, 3 suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, 10 "Phase 1" clinical trials were conducted, 52 "Phase 2" clinical trials and 65 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".